Novo Nordisk Rebuffs $50M Extortion as Focus Shifts to CagriSema FDA Verdict
Published on 06/24/2026 at 15:24 | Redaktion boerse-global.de
Novo Nordisk's shares have climbed nearly 9% over the past week, reclaiming the 200-day moving average at 41.00 euros. But behind the rally lies a tangled narrative: a cyber extortion attempt, a landmark pill approval in the UK, and a multibillion-dollar buyback programme — all overshadowed by a single make-or-break event expected late next year.
The Danish drugmaker refused to pay ransoms demanded by two hacker groups. FulcrumSec sought $25 million, while TheUSERS007 demanded $50 million after breaching internal systems. According to the blog DataBreaches, the attackers exfiltrated pseudonymized clinical trial data. Novo Nordisk stressed that no direct patient identification is possible without additional information. The incident has triggered regulatory investigations and will drive higher IT security costs, though core operations remain unaffected.
Pill Approval Fuels Short-Term Momentum
The immediate catalyst for the share price recovery came from the UK's Medicines and Healthcare products Regulatory Agency, which on June 11 granted marketing authorization for an oral formulation of Wegovy — the first GLP-1 pill for weight loss approved in Britain. Novo Nordisk plans to launch the Wegovy pill outside the US in the second half of 2026. The United Arab Emirates has already issued a similar clearance.
Oral Wegovy sales reached approximately 2.3 billion Danish kroner in the first quarter of 2026, nearly double original expectations. This performance, combined with the UK approval, has helped the stock jump 36% from its March low of 30.25 euros to its current level of around 41.24 euros.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Buyback Provides Technical Support
Management is actively reinforcing the floor. The current share repurchase programme, running until February 2027, allows for buybacks of up to 11.2 billion Danish kroner, part of a total 15 billion kroner commitment. By mid-June, Novo Nordisk had collected nearly 21 million shares, bringing its own holdings to 0.9% of share capital.
Yet the technical picture is fragile. At 41.24 euros, the stock sits only 0.59% above the 200-day moving average — a level that in past downtrends has acted as resistance. The relative strength index of 66.8 suggests the recovery is drifting into overbought territory, raising the likelihood of a pause before the next directional move.
Structural Headwinds Beneath the Surface
The short-term tailwinds mask a tougher underlying reality. Novo Nordisk's full-year 2026 guidance calls for adjusted revenue and operating profit growth of minus 4% to minus 12% at constant exchange rates — the first annual decline in years.
US price erosion is accelerating, driven by lower realized prices, reduced Medicaid reimbursements, and the impact of a most-favored-nation clause agreement. Patent expirations for semaglutide in certain international markets add structural pressure that no single approval can fully offset. Eli Lilly's Zepbound and biosimilar competitors have already chipped away at market share.
The CagriSema Verdict Will Decide the Next Leg
All eyes are now on the FDA, which is expected to rule on Novo Nordisk's next-generation obesity candidate CagriSema by the end of 2026. The REDEFINE-1 study showed a 22.7% average weight loss — short of the company's 25% threshold and below the performance of Lilly's tirzepatide.
A bullish scenario hinges on three pillars: CagriSema's broader clinical profile, which includes dual data for obesity and type 2 diabetes published simultaneously in the Lancet Diabetes & Endocrinology; stronger-than-expected oral Wegovy uptake; and the continuing buyback. A label covering both indications would significantly expand the addressable patient pool. Additionally, a next-generation oral/subcutaneous candidate, Zenagamtide, could extend the franchise well into the next decade.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The bearish case is equally clear. If the FDA grants a narrow label or demands further studies, structural earnings pressures will reassert themselves. In that scenario, the 100-day moving average at 36.48 euros becomes the next support zone.
What to Watch Next
Before the FDA's decision, the second-quarter 2025 earnings report will offer a critical test. Analysts will scrutinize customer retention for the Wegovy pill and whether revenue contraction lands at the top or bottom of the minus 4% to minus 12% range. A decline closer to 4% would bolster the recovery thesis.
For now, the stock is caught between near-term catalysts and a defining long-term verdict. The cyber attack, the pill approval, and the buyback have provided a springboard — but CagriSema alone will determine whether Novo Nordisk can break free of its 200-day ceiling or retreat into a prolonged consolidation.
Ad
Novo Nordisk Stock: New Analysis - 24 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
